News | November 05, 2025
Glenmark Pharmaceuticals USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq Single-Dose Vial
Glenmark will begin distribution in November 2025
Glenmark will begin distribution in November 2025
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
Panacea Biotec receives acceptance from CMSS for supply of bOPV
The inspection was carried out between May 26, 2025 and May 31, 2025
Alembic receives EIR from USFDA for facility at Panelav
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
Hemant Surgical Industries receives order
Subscribe To Our Newsletter & Stay Updated
